Peptide Research Blends¶
HK Peptides Worldwide offers pre-formulated peptide research blends for laboratory protocols requiring synergistic multi-peptide investigation. Each blend is composed of individually manufactured, separately QC-verified components manufactured to identical quality standards — ≥99% HPLC purity, ESI-MS verified per peptide — then combined under controlled conditions with comprehensive batch documentation linking the blend batch number to individual component lot numbers.
Technical Specifications — All Blends¶
| Property | Value |
|---|---|
| Component Purity | ≥99% HPLC per peptide |
| MS Verification | ESI-MS per component |
| Appearance | Lyophilized white powder |
| Solubility | Soluble in sterile water and aqueous buffers |
| Storage | -20°C (lyophilized), 2–8°C (reconstituted) |
BPC-157 + TB-500¶
Healing peptide research combination for angiogenesis and tissue repair models
BPC-157 and TB-500 operate through complementary mechanisms in tissue repair: BPC-157 promotes angiogenesis via VEGFR2-Akt-eNOS signaling and accelerates fibroblast migration, while TB-500 enhances actin polymerization-driven cell migration and endothelial cell survival through Akt pathway activation. This blend is widely utilized in wound healing, tendon/ligament repair, and soft tissue regeneration research protocols.
| Property | Value |
|---|---|
| CAS Components | 137525-51-0 (BPC-157) / 77591-33-4 (TB-500) |
| Available Configurations | 10 mg, 20 mg |
Mechanism of Action¶
- BPC-157: Upregulates VEGF/VEGFR2 signaling, activates FAK-paxillin pathway for fibroblast migration, preserves endothelial tight junction integrity
- TB-500: Sequesters G-actin via LKKTETQ motif, promotes actin polymerization at the leading edge of migrating cells, activates Akt survival signaling
Research Applications¶
- Primary: Synergistic wound healing — combined angiogenesis + cell migration, tendon/ligament repair
- Model Systems: In vitro (HUVEC tube formation, fibroblast scratch co-culture), in vivo (full-thickness wound models, Achilles tendon repair)
Quality Control & Analytical Methods¶
- HPLC: ≥99% purity verification per component at 214/220 nm
- Mass Spectrometry: ESI-MS for molecular weight confirmation of each peptide
- Endotoxin: <1 EU/mg (LAL assay)
- TFA Content: <1% per component (ion chromatography)
Stability & Storage¶
| Condition | Stability |
|---|---|
| -20°C (lyophilized) | 24 months |
| 4°C (lyophilized) | 6 months |
| 25°C (lyophilized) | 1 month |
| Reconstituted (4°C) | 7 days |
| Reconstituted (-20°C) | 30 days |
FAQ¶
Q: What purity level is standard for the BPC-157 + TB-500 blend? A: HK Peptides supplies each component at ≥99% purity by HPLC with full COA documentation covering both peptides.
Q: How should this blend be stored for research use? A: Lyophilized blend should be stored at -20°C. Reconstituted solutions at 4°C for short-term use (up to 7 days).
CJC-1295 + Ipamorelin¶
GHRH + GHS-R dual GH secretagogue stack for pulsatile secretion research
CJC-1295 (no DAC) and Ipamorelin activate complementary signaling pathways at the somatotroph: CJC-1295 activates GHRH-R (Gαs/cAMP), while Ipamorelin activates GHS-R1a (Gαq/Ca²⁺). This dual-pathway approach produces synergistic, supraphysiological GH pulses without the pronounced appetite stimulation and cortisol/prolactin elevation observed with less selective GHS-R1a agonists.
| Property | Value |
|---|---|
| CAS Components | 863288-34-0 (CJC-1295 DAC) / 170851-70-4 (Ipamorelin) |
| Available Configurations | 5 mg CJC + 10 mg Ipamorelin |
Mechanism of Action¶
- CJC-1295: Binds GHRH-R on somatotrophs, activating Gαs/adenylyl cyclase → cAMP → PKA → L-type calcium channel activation → GH exocytosis
- Ipamorelin: Selective GHS-R1a agonist; activates Gαq/PLC → IP₃ → intracellular calcium release → GH exocytosis. Minimal effect on NPY/AgRP appetite neurons compared to GHRP-2 or GHRP-6
Research Applications¶
- Primary: Synergistic GH secretion — combined Gαs/Gαq somatotroph stimulation, pulsatile GH dynamics
- Model Systems: In vitro (dispersed pituitary cell assays), in vivo (GH pulse profiling, IGF-1 response studies)
Quality Control & Analytical Methods¶
- HPLC: ≥99% purity verification per component at 214/220 nm
- Mass Spectrometry: ESI-MS for molecular weight confirmation of each peptide
- Endotoxin: <1 EU/mg (LAL assay)
- TFA Content: <1% per component (ion chromatography)
Stability & Storage¶
| Condition | Stability |
|---|---|
| -20°C (lyophilized) | 24 months |
| 4°C (lyophilized) | 6 months |
| 25°C (lyophilized) | 1 month |
| Reconstituted (4°C) | 7 days |
| Reconstituted (-20°C) | 30 days |
FAQ¶
Q: What purity level is standard for the CJC-1295 + Ipamorelin blend? A: HK Peptides supplies each component at ≥99% purity by HPLC with full COA documentation covering both peptides.
Q: How should this blend be stored for research use? A: Lyophilized blend should be stored at -20°C. Reconstituted solutions at 4°C for short-term use (up to 7 days).
Semaglutide + Cagrilintide¶
GLP-1R + amylin dual pathway metabolic blend for appetite and glycemic research
Semaglutide and Cagrilintide target complementary metabolic pathways: GLP-1R activation on pancreatic β-cells and brainstem nuclei (glucose-dependent insulin secretion, satiety), and amylin receptor activation in the area postrema (gastric emptying, postprandial glucagon suppression). This dual-pathway approach is used in metabolic research to investigate amplified glycemic control and weight-modulatory effects.
| Property | Value |
|---|---|
| CAS Components | 910463-68-2 (Semaglutide) / 1415456-99-3 (Cagrilintide) |
| Available Configurations | 10 mg Cagrilintide + 5 mg Semaglutide |
Mechanism of Action¶
- Semaglutide: GLP-1R agonist → Gαs/cAMP → glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central satiety signaling
- Cagrilintide: Amylin receptor (CTR/RAMP) agonist → area postrema signaling → reduced gastric emptying, postprandial glucagon suppression, enhanced satiety
Research Applications¶
- Primary: Dual incretin/amylin receptor pharmacology — additive/reinforcing metabolic effects
- Model Systems: In vitro (recombinant receptor co-expression assays), in vivo (metabolic phenotyping in diet-induced obesity models)
Quality Control & Analytical Methods¶
- HPLC: ≥99% purity verification per component at 214/220 nm
- Mass Spectrometry: ESI-MS for molecular weight confirmation of each peptide
- Endotoxin: <1 EU/mg (LAL assay)
- TFA Content: <1% per component (ion chromatography)
Stability & Storage¶
| Condition | Stability |
|---|---|
| -20°C (lyophilized) | 24 months |
| 4°C (lyophilized) | 6 months |
| 25°C (lyophilized) | 1 month |
| Reconstituted (4°C) | 7 days |
| Reconstituted (-20°C) | 30 days |
FAQ¶
Q: What purity level is standard for the Semaglutide + Cagrilintide blend? A: HK Peptides supplies each component at ≥99% purity by HPLC with full COA documentation covering both peptides.
Q: How should this blend be stored for research use? A: Lyophilized blend should be stored at -20°C. Reconstituted solutions at 4°C for short-term use (up to 7 days).